[Molecular pathology and targeted therapy of clear cell renal cancer]

Area of Science:

• Oncology
• Molecular Genetics
• Cancer Research

Background:

• Cytokine therapy was the established standard for advanced renal cell cancer (RCC), but yielded limited response rates.
• Recent advances in molecular genetics have identified key targets in RCC, including VHL, angiogenic genotype, and EGFR, particularly in the clear cell variant.

Purpose of the Study:

• To review the evolution of treatment standards in advanced renal cell cancer (RCC).
• To highlight the impact of novel targeted therapies and molecular diagnostics on RCC treatment.
• To explore the potential of molecular diagnostics in personalizing RCC therapy.

Main Methods:

• Review of current literature on advanced renal cell cancer (RCC) treatment.
• Analysis of molecular targets identified through genetic studies in RCC.
• Evaluation of the clinical efficacy of novel targeted agents, specifically multiple tyrosine kinase inhibitors.

Main Results:

• Multiple tyrosine kinase inhibitors have demonstrated significant clinical effectiveness in advanced clear cell renal cancer.
• These targeted agents have successfully shifted the standard of care for advanced RCC.
• The identification of molecular targets and gene defects offers potential for improved therapeutic outcomes.

Conclusions:

• Targeted therapies, particularly tyrosine kinase inhibitors, represent a significant advancement over traditional cytokine therapy for advanced RCC.
• Molecular diagnostics hold promise for identifying specific targets and gene defects in individual tumors.
• Personalized treatment strategies based on molecular profiling may further enhance treatment efficacy in advanced renal cell cancer (RCC).